Related Experiment Videos
International perspectives on AI-driven pharmaceutical IP challenges
Grace Y Wang1, Jian-Ming Hao2, Joe G Chen2
1West Windsor High School-North, West Windsor, NJ, United States.
Abstract:
Artificial Intelligence (AI) is transforming the pharmaceutical sector by optimizing care delivery and accelerating drug design. While AI introduces significant benefits, it presents complex challenges regarding intellectual property (IP) frameworks. This review examines AI-driven innovations in personalized medicine and drug design, with a specific focus on inventorship issues that directly affect pharmaceutical patent protection. We analyze recent United States (US) legal developments concerning AI inventorship, including the US Supreme Court's March 2026 denial of certiorari in Thaler v. Perlmutter, which definitively resolved the question of AI inventorship under US law, provide comparative analyses of approaches in Germany and China, and identify specific lessons, rather than wholesale reforms, that may help stakeholders navigate the evolving intersection of AI and pharmaceutical IP.
Related Concept Videos
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Drug Products: Biologics, Biosimilars and Interchangeables
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Biopharmaceutics and Pharmacokinetics: Overview